Cooper Ronald Harold Wilfred — SEC Form 4 filings
SEC reporting owner CIK 1676880. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-06-10 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 10,000 shares, $57,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 10,000 shares @ $5.70 ($57,000) in enGene Holdings Inc., filed 2024-10-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | CEO & President, Director | 4 | 1 leg · 10,000 sh · $57,000 | — | 3 |
| Generation Bio Co. (GBIO) | Director | 3 | — | — | 8 |
| C4 Therapeutics, Inc. (CCCC) | Director | 3 | — | — | 3 |
Form 4 filings — Cooper Ronald Harold Wilfred
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 62,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Generation Bio Co. (GBIO) | Code (U): 950 · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 1,920 (derivative) · Disposition to issuer (D): 2,500 (derivative) · Disposition to issuer (D): 6,000 (derivative) | EDGAR |
| 2026-02-03 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 801,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 35,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Generation Bio Co. (GBIO) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 850,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | enGene Holdings Inc. (ENGN) | Purchase (P): 10,000 @ $5.70 | EDGAR |
| 2024-07-24 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 1,250,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | C4 Therapeutics, Inc. (CCCC) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Generation Bio Co. (GBIO) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1676880 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →